文献速递自身炎症与 IgG4 相关病

特发性多中心Castleman病伴MEFV基因外显子10新型杂合Ile729Met突变

Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本文报告一例日本iMCD患者,携带家族性地中海热基因(MEFV)外显子10的新型杂合Ile729Met突变;分子动力学模拟显示该突变改变pyrin B30.2结构域局部相互作用,实验提示其有通过炎症小体激活增加炎症因子的潜力,患者经IL-6抑制剂治疗缓解12个月。

要点

  • iMCD患者可携带MEFV基因新型杂合突变,提示自身炎症机制参与。
  • 该Ile729Met突变经分子动力学模拟改变pyrin B30.2域局部相互作用。
  • 患者经IL-6抑制剂治疗成功并维持缓解12个月。

核心结论

  • 该患者MEFV基因突变所致pyrin功能异常可能通过炎症小体信号诱导IL-6产生,参与MCD发生。

研究设计与样本

  • 个案报告,对一例日本iMCD患者行靶向二代测序和Sanger测序的基因分析,并进行分子动力学模拟。

主要发现

  • 患者2011年2月基于颈部及肺门淋巴结病、典型肺部病变和颈部淋巴结活检被诊断为IgG4相关病,因无症状未治疗随访。
  • 患者自2017年6月起出现持续疲劳、发热伴CRP升高,腋窝淋巴结活检诊断为iMCD。
  • 基因分析发现MEFV基因外显子10新型杂合Ile729Met突变;分子动力学模拟显示该突变显著改变人pyrin B30.2域局部相互作用。
  • 实验提示该突变有通过炎症小体激活增加炎症细胞因子的潜力。
  • 患者经IL-6抑制剂治疗成功,已维持缓解12个月。

临床怎么用

  • 对iMCD患者可考虑筛查遗传性自身炎症疾病相关基因,以识别潜在自身炎症机制。
  • IL-6抑制剂可用于此类iMCD患者的治疗并可实现缓解。

局限性

  • 为单一病例报告,结论的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While the aetiology of idiopathic multicentric Castleman disease (iMCD) remains unclear, the involvement of autoinflammatory mechanisms has been suggested. Herein we report a Japanese patient with iMCD with a novel heterozygous Ile729Met mutation in exon 10 of the Mediterranean fever (MEFV) gene. METHODS: We performed genetic analysis via targeted next-generation sequencing analysis and Sanger sequencing and conducted molecular dynamics simulations to investigate the hydrophobic interactions around the 729th amino acid in human pyrin. RESULTS: In February 2011, a 59-year-old man was diagnosed with IgG4-related disease at our department based on the findings of cervical and hilar lymphadenopathies, typical lung lesions and cervical lymph node biopsy. The patient was followed up without treatment, as he was asymptomatic. However, he had been experiencing prolonged fatigue and fever with high levels of CRP since June 2017. Axillary lymph node biopsy findings led to the diagnosis of iMCD. He was successfully treated with an IL-6 inhibitor and has been in remission for 12 months. Genetic analyses for hereditary autoinflammatory disease-related genes were performed, revealing a novel heterozygous Ile729Met mutation in exon 10 of the MEFV gene. We identified that this novel mutation significantly altered the local interaction of the human pyrin B30.2 domain by molecular dynamics simulation analysis and experimentally had the potential for inflammasome activation with increased inflammatory cytokines. CONCLUSION: The abnormal function of pyrin due to a mutation in the MEFV gene in this patient may have contributed to the development of MCD by inducing IL-6 production via inflammasome signalling.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Endo Y, Koga T, Otaki H, et al. Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene. Rheumatology (Oxford). 2021. PMID: 32830263. doi:10.1093/rheumatology/keaa269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。